This study measures the impact of Medicaid formulary restrictions on the rate at which patients who failed on a drug therapy for schizophrenia return to the same therapy.
Ryan M. Conrad, PhD
Advertisement
Articles by Ryan M. Conrad, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
Ochsner Health, Paradigm Health Partnership Expands Clinical Trial Access Across the Gulf South
5